Abstract: The present invention relates to nucleic acid molecules encoding hypusines mutants having the biological activity of an inhibitor of cellular proliferation. The present invention further relates to vectors comprising said nucleic acid molecules, to hosts transformed with said vectors, to methods of producing the polypeptide encoded by the nucleic acid molecule of the invention as well as to the polypeptide itself. In addition, the present invention relates to pharmaceutical and diagnostic compositions comprising one or more of the aforementioned compounds, the methods for synchronizing cell growth and to the use of the vector of the invention in gene therapy.
Type:
Grant
Filed:
March 15, 2000
Date of Patent:
September 10, 2002
Assignee:
Max-Planck-Gesellschaft zur Förderung der Wissenschaften
e.V.
Inventors:
Craig Young, Friedrich Lottspeich, Adam Otasek
Abstract: The present invention relates to a recombinant viral nucleic acid selected from a (+) sense, single stranded RNA virus possessing a native subgenomic promoter encoding for a first viral subgenomic promoter, a nucleic acid sequence that codes for a viral coat protein whose transcription is regulated by the first viral subgenomic promoter, a second viral subgenomic promoter and a second nucleic acid sequence whose transcription is regulated by the second viral subgenomic promoter. The first and second viral subgenomic promoters of the recombinant viral nucleic acid do not have homologous sequences relative to each other. The recombinant viral nucleic acid provides the particular advantage that it systemically transcribes the second nucleic acid in the host. Host organisms encompassed by the present invention include procaryotes and eucaryotes, particularly animals and plants.
Type:
Grant
Filed:
November 28, 2000
Date of Patent:
September 10, 2002
Assignee:
Large Scale Biology Corporation
Inventors:
Jon Donson, William O. Dawson, George L. Grantham, Thomas H. Turpen, Ann M. Turpen, Stephen J. Garger, Laurence K. Grill
Abstract: The present invention provides an AAV vector having a foreign DNA coding for a protein that boosts immunogenicity of cells. The invention also provides a vaccine containing such a vector and the use of both.
Type:
Grant
Filed:
October 9, 2000
Date of Patent:
September 10, 2002
Assignee:
MediGene AG
Inventors:
Gerhard Maass, Michael Hallek, Christoph Bogedain
Abstract: The invention provides a method for treating vaginal dryness by increasing hydration and lubrication of vaginal and cervical tissues in a subject in need of such treatment. The method comprises administering to the subject a nicotinic acetylcholine receptor agonist such as nicotine and its analogs, transmetanicotine and its analogs, epibatidine and it analogs, lobeline and its analogs, pyridol derivatives, para-alkylthiophenol derivatives, and imidacloprid and its analogs, in an amount effective to stimulate cervical and vaginal secretions. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the formulation include: topical administration via a liquid, gel, cream, ointment, foam, pessary, or tablet; systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form (liquid or pill), injectable, suppository form, or transdermal form. The invention is useful for treating vaginal dryness and vulvar pain.
Abstract: A solid phase synthesis method for the preparation of diverse sequences of separate polymers or nucleic acid sequences using electrochemical placement of monomers of nucleic acids at a specific location on a substrate containing at least one electrode that is preferably in contact with a buffering or scavenging solution to prevent chemical crosstalk between electrodes due to diffusion of electrochemically generated reagents.
Abstract: Novel enzymatically produced melanins are described that are useful in the treatment of HIV infection. The novel melanins are optionally modified to contain chemical moieties such as halogens, sulfates, or sulfonyl groups. Additionally, the novel enzymatically synthesized melanins may be modified, or further modified, by chemical oxidation.
Abstract: The present invention relates to a transduction system, comprising (a) a rep-negative AAV vector containing a foreign DNA and (b) a product providing an AAV Rep protein. The invention also relates to the use of the transduction system.
Type:
Grant
Filed:
January 30, 2001
Date of Patent:
August 27, 2002
Assignee:
Medigene, AG
Inventors:
Gerd Maass, Christoph Bogedain, Michael Hallek, Clemens Wendtner, Doris Michl
Abstract: A method for extracting proteins from the intercellular space of plants is provided. The method is applicable to the large scale isolation of many active proteins of interest synthesized by plant cells. The method may be used commercially to recover recombinantly produced proteins from plant hosts thereby making the large scale use of plants as sources for recombinant protein production feasible.
Type:
Grant
Filed:
November 28, 2000
Date of Patent:
August 27, 2002
Assignee:
Large Scale Biology Corporation
Inventors:
Thomas H. Turpen, Stephen J. Garger, Michael J. McCulloch, Terri I. Cameron, Michelle L. Samonek-Potter, R. Barry Holtz
Abstract: The present invention provides an integrated, fully automated, high-throughput system for two-dimensional electrophoresis comprised of gel-making machines, gel processing machines, gel compositions and geometries, gel handling systems, sample preparation systems, software and methods. The system is capable of continuous operation at high-throughput to allow construction of large quantitative data sets.
Type:
Grant
Filed:
August 17, 2000
Date of Patent:
August 20, 2002
Assignee:
Large Scale Biology Corporation
Inventors:
N. Leigh Anderson, Norman G. Anderson, Jack Goodman
Abstract: Acetobacter strains are identified as stable under agitated culture conditions and exhibit substantially reduced gluconic and keto-gluconic acids production. A method and media for producing bacterial cellulose under agitated culture conditions resulting in sustained production over an average of 70 hours of at least 0.1 g/liter per hour are achieved. A unique reticulated cellulose product is produced using the methods and conditions claimed, and may be converted to of a sheet characterized by substantial resistance to densification and great tensile strength when produced by sheet forming means. Preferred Acetobacter strains are ATCC Nos. 53264, 53263 and 53524.
Type:
Grant
Filed:
June 1, 1993
Date of Patent:
August 6, 2002
Assignee:
CP Kelco U.S., Inc.
Inventors:
Arie Ben-Bassat, Robert Bruner, Sharon Shoemaker, Yehoshua Aloni, Harry Wong, Donald C. Johnson, Amar N. Neogi
Abstract: The present invention provides a method of compiling a plant functional gene profile, a method of changing the phenotype or biochemistry of a plant, a method of determining a change in phenotype or biochemistry of a plant, and a method of determining the presence of a trait in plant. The methods comprise expressing transiently a nucleic acid sequence of a plant into a host plant to affect phenotypic or biochemical changes in the host plant. A viral vector functional genomic screen has been developed to identify nucleotide sequences in transfected plants by systemically knocking out endogenous gene expression in an antisense mechanism. Once the presence of a trait in a plant is identified by phenotypic or biochemical changes in the host plant, the nucleic acid insert in the cDNA clone or in the vector that results in the changes is then sequenced. The present invention exemplifies that genes encoding GTP binding proteins in one plant can silence endogenous gene expression in a different plant.
Type:
Grant
Filed:
July 21, 1999
Date of Patent:
July 30, 2002
Assignee:
Large Scale Biology Corporation
Inventors:
Monto H. Kumagai, Guy R. della-Cioppa, Robert L. Erwin, David R. McGee
Abstract: The present invention provides a recombinant &agr;-L-iduronidase and biologically active fragments and mutants thereof, methods to produce and purify this enzyme as well as methods to treat certain genetic disorders including- &agr;-L-iduronidase deficiency and mucopolysaccharidosis I (MPS 1).
Type:
Grant
Filed:
November 12, 1999
Date of Patent:
July 30, 2002
Assignee:
Harbor-UCLA Research and Education Institute
Abstract: A method of promoting drainage of congested middle ear fluid in a subject in need of such treatment is disclosed. The method comprises administering to the middle ear of the subject a uridine triphosphate such as uridine 5′-triphosphate (UTP), an analog of UTP, or any other analog, in an amount effective to promote drainage of congested middle ear fluid by hydrating mucous secretions in the middle ear or by stimulating ciliary beat frequency in the middle ear or eustachian tube. The method is useful for treating patients afflicted with otitis media and other middle ear diseases, otitis externa, and inner ear diseases including Ménière's Disease. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include any liquid suspension (including nasal drops or spray), oral, inhaled by nebulization, topical, injected or suppository form.
Type:
Grant
Filed:
February 21, 1996
Date of Patent:
July 23, 2002
Assignee:
Inspire Pharmaceuticals, Inc.
Inventors:
David J. Drutz, Janet L. Rideout, Karla M. Jacobus
Abstract: A method of stimulating ciliary beat frequency in a subject in need of such treatment is disclosed. The method comprises administering to the airways, ears, eyes, or genito-urinary tract of the subject a triphosphate nucleotide such as uridine 5′-triphosphate (UTP), an analog of UTP, or any other analog, in an amount effective to stimulate ciliary beat frequency. This method is useful for treating patients afflicted with ciliary dyskinesia, Kartagener's syndrome, or any other disease involving dysfunction of ciliary movement, such as male infertility caused by impairment of propulsion of the spermatozoa or immune deficiency caused by impairment of ciliary movement in neutrophils or macrophages. Pharmaceutical formulations and methods of making the same are also disclosed.
Type:
Grant
Filed:
July 17, 1998
Date of Patent:
July 16, 2002
Assignees:
Inspire Pharmaceuticals, Inc., The University of North Carolina at Chapel Hill
Inventors:
Karla M. Jacobus, Benjamin R. Yerxa, William Pendergast, Richard C. Boucher, Jr., Janet L. Rideout, David J. Drutz, Michael K. James, Monroe Jackson Stutts, Cary Geary, Edwardo R. Lazarowski
Abstract: The invention relates to dendrimers comprising an initiator core with at least two functional groups and at least two saccharides, a process for preparing sch dendrimers as well as uses thereof.
Type:
Grant
Filed:
March 8, 1999
Date of Patent:
July 9, 2002
Assignee:
Deutsches Krebsforschungzentrum Stiftung des Offentlichen
Rechts
Inventors:
Manfred Wiessler, Markus Gschrey, Willi Von der Lieth, Walter Mier
Abstract: The present invention relates to a conjugate comprising an active substance and a compound having a binding site for metallic compounds. In addition, this invention relates to a process for the preparation of such a conjugate and its use.
Type:
Grant
Filed:
February 9, 1998
Date of Patent:
June 25, 2002
Assignee:
Deutsches Krebsforschungszentrum Stiftung Des
Öffentlichen Rechts
Inventors:
Hannsjörg Sinn, Wolfgang Maier-Borst, Hans-Hermann Schrenk, Gerd Stehle
Abstract: Methods and compositions are provided for the creation and screening of non-human animal models having many of the histologic characteristics of human psoriasis. Immunocompromised host animals are injected with a purified population of CD45Rb positive cells, which are tolerant of the host major histocompatibility antigens, but are mismatched at one or more minor antigens. The injected cells are stimulated with a pro-inflammatory cytokine, e.g. IL-12, and a polyclonal activating agent. The injected animals develop a chronic skin disorder that includes histological features observed in human psoriasis, e.g. rete pegs, severe acanthosis and infiltration of Th1 cells into the dermis.
Abstract: The invention relates to a magnetic pin (8, 22) for concentrating particles, containing
(a) a grip adapter (2, 14),
(b) a connecting pin (4, 16) with dents (3, 15),
(c) at least one magnet (7, 20) and
(d) a sheath (5, 18).
Abstract: Disclosed is a 6 kDa host-defense polypeptide which is generated by proteolytic digestion of the lactoferrin molecule. The 6 kDa host-defense polypeptide has antimicrobial activity and also endotoxin-neutralizing activity. Also disclosed are functional variants of the 6 kDa host defense polypeptide, which include N-terminal and C-terminal truncations of the 6 kDa polypeptide, and other modifications of the polypeptide, such as amino acid substitutions which preserve or enhance activity.
Abstract: The invention provides novel genetic constructions for the expression of inhibitory RNA in the cytoplasm of eukaryotic cells. The inhibitory RNA may be an anti-sense RNA or a co-suppressor RNA, and functions to reduce the expression of a gene of interest in the target cell. The genetic constructions of the invention are capable of replicating in the cytoplasm of a eukaryotic cell and comprise a promoter region in functional combination with an encoding polynucleotide. The genetic constructions may be designed so as to replicate in the cytoplasm of plant cells, yeast cells, and mammalian cells. When the eukaryotic cell of interest is a plant cell, the genetic construction is preferably derived from a plant RNA virus. Plant RNA virus derived genetic constructions may employ a plant virus subgenomic promoter, including subgenomic promoters from tobamoviruses in functional combination with the RNA encoding region.
Type:
Grant
Filed:
November 8, 1999
Date of Patent:
April 23, 2002
Assignee:
Large Scale Biology Corporation
Inventors:
Monto H. Kumagai, Guy R. Della-Cioppa, Jonathan Donson, Damon A. Harvey, Laurence K. Grill